Prescient Therapeutics delivers new clinic-ready cell therapy technology
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke outlines the company's oncology treatment vision in a new...
Prescient Therapeutics Ltd (ASX:PTX)'s Steven Yatomi-Clarke outlines the company's oncology treatment vision in a new...
Australian biotech company Prescient Therapeutics has publicly revealed its high-performing cell therapy enhancement platform named...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest technology in its portfolio, a...
Prescient Therapeutics (PTX) has unveiled its new cell therapy manufacturing enhancement technology, CellPryme-M.
In an upbeat development, clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has rolled out a second cell...
Prescient is continuing to be a powerful force in the burgeoning personalised cancer treatment therapy...
Prescient Therapeutics (ASX: PTX) Managing Director and Chief Executive Officer Steven Yatomi-Clarke joins ASX Investor...
Prescient Therapeutics Limited (ASX: PTX), a clinical-stage oncology company, has taken another step towards advancing...
Prescient Therapeutics (ASX: PTX) signed off the March quarter with major progress made in its Cell...
According to the World Health Organisation, cancer accounted for nearly 10 million deaths in 2020,...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.